Jennifer Brigitte Green, MD

Professor of Medicine
Member in the Duke Clinical Research Institute
Campus mail 200 Morris Street, Room 7114, P.O. Box 17969, Durham, NC 27715
Phone (919) 668-8725
Email address green094@mc.duke.edu

Diabetes Mellitus: Prevention strategies, predictors, treatment effects, complications and cardiovascular outcomes. Utilization of EHR data to construct tools to improve the care of diabetes and comorbid conditions.

Education and Training

  • Fellowship, Endocrinology, Metabolism And Nutrition, Duke University School of Medicine, 1996 - 1998
  • Resident, Internal Medicine, University of North Carolina at Chapel Hill School of Medicine, 1994 - 1996
  • Intern, Internal Medicine, University of North Carolina at Chapel Hill School of Medicine, 1993 - 1994
  • M.D., University of Virginia, 1993

Publications

Guimarães, Patrícia O., Eric D. Peterson, Susanna R. Stevens, Yuliya Lokhnygina, Jennifer B. Green, Darren K. McGuire, Rury R. Holman, and Renato D. Lopes. “Antithrombotic treatment gap among patients with atrial fibrillation and type 2 diabetes..” Int J Cardiol 289 (August 15, 2019): 58–62. https://doi.org/10.1016/j.ijcard.2019.04.085.

PMID
31079973
Full Text

Standl, Eberhard, Jennifer B. Green, Rury R. Holman, and Rury R. TECOS Study Group. “Comment on Davis et al. Effects of Severe Hypoglycemia on Cardiovascular Outcomes and Death in the Veterans Affairs Diabetes Trial. Diabetes Care 2019;42:157-163..” Diabetes Care 42, no. 6 (June 2019). https://doi.org/10.2337/dc18-2597.

PMID
31110121
Full Text

Montvida, O., J. B. Green, J. Atherton, and S. K. Paul. “Treatment with incretins does not increase the risk of pancreatic diseases compared to older anti-hyperglycaemic drugs, when added to metformin: real world evidence in people with Type 2 diabetes..” Diabet Med 36, no. 4 (April 2019): 491–98. https://doi.org/10.1111/dme.13835.

PMID
30306620
Full Text

Wittbrodt, Eric T., James M. Eudicone, Kelly F. Bell, Devin M. Enhoffer, Keith Latham, and Jennifer B. Green. “Authors' reply to "Comment on generalizability of GLP-1 RA CVOTs in US T2D population"..” Am J Manag Care 25, no. 4 (April 2019): 171–72.

PMID
30986013
Scholars@Duke

Shavadia, Jay, Yinggan Zheng, Jennifer B. Green, Paul Armstrong, Cynthia Westerhout, Darren McGuire, Matthew Roe, J. H. Cornel, Rury Holman, and Eric D. Peterson. “ASSOCIATIONS BETWEEN BETA-BLOCKER THERAPY AND CARDIOVASCULAR OUTCOMES IN PATIENTS WITH DIABETES AND ESTABLISHED ATHEROSCLEROTIC CARDIOVASCULAR DISEASE: INSIGHTS FROM THE TECOS STUDY.” In Journal of the American College of Cardiology, 73:138–138. Elsevier BV, 2019. https://doi.org/10.1016/s0735-1097(19)30746-6.

Full Text

Fanaroff, Alexander C., Robert Clare, Karen S. Pieper, Kenneth W. Mahaffey, Chiara Melloni, Jennifer B. Green, John H. Alexander, et al. “Frequency, Regional Variation, and Predictors of Undetermined Cause of Death in Cardiometabolic Clinical Trials: A Pooled Analysis of 9259 Deaths in 9 Trials..” Circulation 139, no. 7 (February 12, 2019): 863–73. https://doi.org/10.1161/CIRCULATIONAHA.118.037202.

PMID
30586739
Full Text

McHugh, Kelly, Adam D. DeVore, Jingjing Wu, Roland A. Matsouaka, Gregg C. Fonarow, Paul A. Heidenreich, Clyde W. Yancy, Jennifer B. Green, Natasha Altman, and Adrian F. Hernandez. “Heart Failure With Preserved Ejection Fraction and Diabetes: JACC State-of-the-Art Review..” J Am Coll Cardiol 73, no. 5 (February 12, 2019): 602–11. https://doi.org/10.1016/j.jacc.2018.11.033.

PMID
30732715
Full Text

Packer, M., J. Butler, G. S. Filippatos, W. Jamal, A. Salsali, J. Schnee, K. Kimura, et al. “Evaluation of the effect of sodium–glucose co-transporter 2 inhibition with empagliflozin on morbidity and mortality of patients with chronic heart failure and a reduced ejection fraction: rationale for and design of the EMPEROR-Reduced trial.” European Journal of Heart Failure, January 1, 2019. https://doi.org/10.1002/ejhf.1536.

Full Text

Bethel, M Angelyn, Samuel S. Engel, Susanna R. Stevens, Yuliya Lokhnygina, Jie Ding, Robert G. Josse, Michael Alvarsson, et al. “Progression of glucose-lowering diabetes therapy in TECOS..” Endocrinol Diabetes Metab 2, no. 1 (January 2019). https://doi.org/10.1002/edm2.53.

PMID
30815579
Full Text

Herrington, William G., David Preiss, Richard Haynes, Maximilian von Eynatten, Natalie Staplin, Sibylle J. Hauske, Jyothis T. George, et al. “The potential for improving cardio-renal outcomes by sodium-glucose co-transporter-2 inhibition in people with chronic kidney disease: a rationale for the EMPA-KIDNEY study..” Clin Kidney J 11, no. 6 (December 2018): 749–61. https://doi.org/10.1093/ckj/sfy090.

PMID
30524708
Full Text

Pages